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Summary
Background There is conclusive evidence from clinical trials
that reduction of mortality by fibrinolytic therapy in acute
myocardial infarction is related to the time elapsing
between onset of symptoms and commencement of
treatment. However, the exact pattern of this relation
continues to be debated. This paper discusses whether or
not appreciable additional gain can be achieved with very
early treatment.
Methods The relation between treatment delay and short-
term mortality (up to 35 days) was evaluated using
tabulated data from all randomised trials of at least 100
patients (n=22; 50 246 patients) that compared fibrinolytic
therapy with placebo or control, reported between 1983
and 1993.
Findings Benefit of fibrinolytic therapy was 65 (SD 14), 37
(9), 26 (6) and 29 (5) lives saved per 1000 treated patients
in the 0–1, 1–2, 2–3, and 3–6 h intervals, respectively.
Proportional mortality reduction was significantly higher in
patients treated within 2 h compared to those treated later
(44% [95% CI 32, 53] vs 20% [15, 25]; p=0·001). The
relation between treatment delay and mortality reduction
per 1000 treated patients was expressed significantly
better by a non-linear (19·4–0·6x+29·3x1) than a linear
(34·7–1·6x) regression equation (p=0·03).
Interpretation The beneficial effect of fibrinolytic therapy is
substantially higher in patients presenting within 2 h after
symptom onset compared to those presenting later.
Lancet 1996; 348: 771–75
Introduction
The reduction in mortality that can be achieved with
reperfusion therapy in patients with evolving myocardial
infarction depends on the time elapsing between onset of
symptoms and initiation of treatment or, more specifically,
on the duration of coronary occlusion before reperfusion.1
Although earlier reperfusion yields a better clinical
outcome the relation between treatment delay and
mortality reduction is controversial. A key question is
whether or not a substantial additional reduction of the
mortality risk can be achieved with very early treatment,
ie, within 2–3 h after onset of symptoms. The concept of a
‘first golden hour’2 is supported both by experimental
studies and randomised trials comparing pre-hospital with
in-hospital therapy.2,3 By contrast, the Fibrinolytic
Therapy Trialists’ (FTT) Collaborative Group, in a
pooled dataset of randomised trials of more than 1000
patients,4 reported only a gradual decrease of benefit with
longer delay. We present an alternative analysis of data
from previous trials. 
Experimental studies
The duration of coronary occlusion and the extent of
collateral circulation are the main determinants of infarct
size in pigs, dogs, cats, and other animals.5–7 In animals
with a coronary collateral circulation similar to that of
humans an occlusion persisting for 15–30 min generally
does not lead to significant myocardial damage.6,7 Thus,
necrosis can be prevented provided reperfusion is achieved
within this period.8 A small area of necrosis usually occurs
with reperfusion after 45 min occlusion, while the mid-
endocardial and subendocardial zones are still viable.6
Longer durations of coronary occlusion result in
progressive growth of the infarction and reduction of the
amount of salvageable myocardium. At 90 min the extent
of cell death involves 40–50% of the area at risk; less than
half of the jeopardised myocardium remains viable at that
time.3,6 6 h after the onset of continuous ischaemia the area
at risk is fully infarcted such that myocardial salvage will
be minimal.
In humans, the thrombotic event frequently consists of
multiple cycles of temporary occlusion and reperfusion.
The degree of chest pain (if present) varies among patients
so that it is often difficult to determine the exact duration
of the coronary occlusion. Nevertheless, data indicate that
evolution of (enzymatically detectable) infarct size over
time in humans shows a pattern similar to that in animals.9
Pre-hospital versus in-hospital thrombolysis
Various clinical trials have shown that early restoration of
coronary patency improves survival.10–13 Later
recanalisation may also be beneficial, particularly in
patients with sufficient collateral flow and in those with
stuttering infarction. Randomised trials comparing pre-
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to this analysis little would be gained by extra efforts to
achieve very early, prehospital, therapy.
Alternative presentation of trial data
Since the FTT analysis is at variance with the
experimental data, and with the larger benefit found in
direct, randomised comparison of prehospital with in-
hospital therapy, an alternative presentation of the trial
data seems appropriate. Furthermore, estimations of
benefit for early treatment in the FTT analysis may have
been influenced by the chosen framework for analysis.
The inclusion-threshold of 1000 patients for each of the
nine studies included in the FTT analysis is rather
arbitrary. There is no good reason to exclude smaller
trials. Although the number of patients in the smaller
studies may not be sufficient to prove the effect of
thrombolytic therapy, these studies may nevertheless assist
a more powerful estimation of treatment effects in
subgroups of patients in a pooled dataset; more so,
because several smaller studies excluded from the FTT
analysis included a significant proportion of patients who
were treated very early.
The statistical analysis was based on subdivision of
patients according to delay from symptom onset with only
two benefit estimations in the first 3 h (at average delay
times of 0·98 and 2·50 h, respectively). In this way, part of
a potential large effect in the first 2 h may be obscured by
a relatively small effect in the third hour. A more
differentiated subdivision seems more appropriate to study
the effect of very early therapy.23 Furthermore, non-linear
models might be developed and tested in addition to the
linear FTT model.
Methods
For the reasons given, we studied the delay/benefit relation in a
modified dataset, covering all randomised trials of fibrinolytic
therapy versus placebo or control which included at least 100
patients. These trials were reported between 1983 and 1993 and
indexed in the MEDLINE information system.24 There are 22
such trials12,13,25–44 The indication for fibrinolytic therapy in two of
the trials may not have been appropriate: the USIM trial included
a high proportion (32%) of patients with unstable angina, and the
ISIS-3 uncertain indication group consisted of patients without or
with only minor ST elevation;43,44 these patient subgroups are
unlikely to benefit from fibrinolysis.45–47 The USIM and ISIS-3
trials included 4250 patients who were treated within 3 h of
symptom onset and may therefore seriously bias benefit
estimations for early treatment of those with confirmed infarction.
Accordingly, we analysed data from previous trials both with and
without inclusion of USIM and the ISIS-3 uncertain indication
group.
Tabulated data were collected on time from symptom onset
and short-term mortality (up to 35 days). Mortality observations
of the separate trials were positioned at the average treatment
delay, if reported, and otherwise at the mid-point of the described
time-window. The data of 11 trials were sufficiently detailed to be
split into different time intervals.12,13,27,29,31–33,41–44 Patients were
subsequently allocated to six subgroups according to treatment
delay (0–1, 1–2, 2–3, 3–6, 6–12, and 12–24 h from
symptom onset to randomisation). Absolute and relative
mortality effects of fibrinolytic therapy were evaluated in each of
these categories. USIM and ISIS-3 uncertain indication patients
were excluded from this analysis.
Benefit was defined as the absolute mortality reduction,
calculated as the difference in the percentage dying in the
fibrinolytic group and the controls (we also calculated the SD and
95% CI of this difference). Linear (+x) and non-linear
(+x+x2 and +x+x1) regression analyses were performed
to determine the relation between benefit and treatment delay.
hospital with in-hospital therapy14–21 have shown a
substantial beneficial effect of very early thrombolytic
therapy. Although these studies were too small to show
statistical significance, such significance was reached in
pooled analyses of the data.2,22 The largest EMIP trial, with
5469 randomised patients, reported 15 (SD 8) additional
patients alive at 30 days per 1000 patients as a result of 1 h
earlier treatment.21 Figure 1 shows the weighted regression
line of all eight randomised studies.14–21 In these studies,
the average delay from symptom onset to initiation of
therapy was 2·1 h in the prehospital patients and 3·1 h in
the inhospital patients. 1 h earlier treatment within 3 h
from symptom onset is associated with a benefit of 21 (6)
lives per 1000 treated (p=0·002).
FTT analysis
The Fibrinolytic Therapy Trialists’ Collaborative Group
presented a systematic analysis of the pooled data from all
unconfounded trials of fibrinolytic therapy versus control
or placebo that randomised at least 1000 patients with
suspected myocardial infarction.4 Nine trials were
included with 58 600 patients, among whom 6177 deaths
(10·5%) were reported within 35 days. The effect of
treatment on mortality and morbidity was studied in
various patient categories. One of the FTT subanalyses
described the benefits of fibrinolytic therapy in five
subgroups according to the delay from symptom onset to
randomisation (0–1, 1–3, 3–6, 6–12 and 12–24 h).
Mortality reduction was highest among patients
presenting in hospital within 1 h: the absolute benefit was
35 (11) additional patients alive per 1000 treated. In
patients presenting 1–3 and 3–6 h the benefits were 25
(5) and 19 (5) additional alive patients per 1000 treated,
respectively.
In patients with ST elevation or bundle branch block
(n=45 000, 77% of the population) the absolute effects of
fibrinolytic therapy were slightly larger. Benefits per 1000
treated patients were 39 (12), 30 (5), 27 (6), 21 (7), and
7 (7) in the respective subgroups. The relation between
these benefits and the average delay from symptom onset
(0·98, 2·50, 4·79, 9·11, and 17·48 h, respectively) was
described as a straight regression line. Every additional
hour of treatment delay from onset of symptoms was
associated with a reduction in benefit by approximately
1·6 (0·6) lives per 1000 patients.
The FTT investigators concluded from these data a
gradually increasing benefit with earlier treatment, without
significant additional treatment effect at 0–1 h. According
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Figure 1: Mortality at 35 days in randomised studies
comparing prehospital (circles) with inhospital (squares)
thrombolytic therapy
All trials (except that of Castaigne) showed trend favouring prehospital
thrombolysis. Regression line (bold, weighted by number of patients
included in mortality result) was mainly determined by EMIP study.
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Regression functions were fitted in the tabulated data from the
separate trials. Data were weighted by the inverse of the variance
of the absolute benefit described.4 Goodness of fit was expressed
as the ratio of regression sum of squares and total sum of squares
(R2-value). Regression analyses were performed both with and
without USIM and ISIS-3 uncertain indication data.
Results
The 22 trials included a total of 50 246 patients, of whom
5762 (11%) were randomised within 2 h of symptom
onset and another 10 435 (21%) between 2 and 3 h.
Fibrinolytic therapy appeared to be beneficial up to at
least 12 h (figure 2). The absolute reduction in mortality
was greatest among patients who presented within 1 h of
symptom onset (average delay 0·75 h). Benefit in this
group was estimated at 65 (SD 14; 95% CI 38, 93) lives
saved per 1000 treated patients, which is higher than the
FTT estimation of benefit at nearly the same time point
(0·98 h) of 35 (11). Benefit was also higher in our analysis
than in the FTT analysis among patients randomised in
the second hour (37 [9]; 20, 55) per 1000 treated. The
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Figure 2: Mortality at 35 days among fibrinolytic-treated and
control patients, according to treatment delay
Figure 4: Absolute 35-day mortality reduction versus treatment
delay
Small closed dots: information from trials included in FTT analysis; open
dots: information from additional trials; small squares: data beyond
scale of x/y cross. The linear (34·7–1·6x) and non-linear
(19·4–0·6x+29·3x1) regression lines are fitted within these data,
weighted by inverse of the variance of the absolute benefit in each
datapoint.4 Black squares: average effects in six time-to-treatment
groups (areas of squares inversely proportional to variance of absolute
benefit described).
Figure 3: Proportional effect of fibrinolytic therapy on 35-day
mortality according to treatment delay
Odds ratios, plotted with 95% CI on a log scale, are significantly
different over the six groups (Breslow-Day test, p=0·001). Areas of
black squares proportional to amount of statistical information
benefit per 1000 treated in the subgroups presenting at
2–3 h, 3–6 h, 6–12 h, and 12–24 h was respectively
26 (6; 14, 37), 29 (5; 19, 40), 18 (6; 7, 29), and 9 (7; 5,
22).
Similarly, the proportional mortality reduction was
highest in the 1 h patients (48% [95% CI 31, 61]; figure
3), and significantly higher in patients treated within 2 h
than in those treated later (44% [32, 53] and 20% [15,
25], respectively). By contrast with the FTT report, odds
ratios differed significantly over the time-to-treatment
groups (p=0·001, figure 3).
The relation between absolute benefit of fibrinolytic
therapy and treatment delay can be described by a linear
function, similar to FTT, which shows a significant
reduction in benefit of approximately 1·6 (0·5) lives per
1000 patients per hour of treatment delay (H0: =0
rejected; p<0·01: R2=0·22). This linear model was not
significantly improved by addition of the term x2 (H0: =0
not rejected; p=0·29; R2=0·25). However, the component
x1 of the second non-linear model had a significant
contribution to the regression function (H0: =0 rejected;
p=0·03). In fact, this latter model fits best with the data
(R2=0·32), in particular with the early observations (figure
4). Inclusion of the USIM and ISIS-3 uncertain indication
data and exclusion of the intracoronary studies
(WWashICy26 and ICINy28) did not essentially change
these findings. Further analyses were performed including
all trials with at least 1000 (FTT dataset), 500 and 250
patients, respectively. In all cases, the second non-linear
model was significantly better than the linear model.
Discussion
In animals with a coronary circulation similar to that of
humans, the amount of myocardial tissue that is
salvageable directly depends on the duration of coronary
occlusion. This dependency is non-linear. Very early
reperfusion of the occluded coronary artery (within
30 min) may lead to full recovery of ischaemic tissue and
thus prevent necrosis. In experimental models most of the
irreversible damage to the myocardium occurs between
1 and 2 h, after the occlusion, and little or no salvage can
be achieved after 6 h of occlusion.
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These findings correspond very well with the relation
between infarct size estimated by assay of cardiac enzymes
and the delay in thrombolytic treatment, as measured in
1334 patients with evolving myocardial infarction.9 The
cumulative release of myocardial -hydroxybutyrate
dehydrogenase during the first 72 h after infarction (Q72)
was comparatively small in patients treated within 1 h
from onset of symptoms. A very steep increase in the rate
of enzyme release was noted between 1 and 2 h of
treatment delay (the increase was relatively small
thereafter). The life-saving effect of very early reperfusion
therapy has been supported by pooled analyses of studies
which randomised between immediate, prehospital
initiation of therapy and delayed, inhospital therapy
(figure 1).2,22
This advantage of very early therapy in the prehospital
studies is much larger than the effect of 1 h earlier
treatment reported by the FTT investigators (1·6 lives per
1000 treated), who compared inhospital thrombolytic with
placebo or conventional therapy.4 We emphasise that
patients with a short treatment delay tend to differ from
those who wait longer before seeking medical help: many
of the patients with very large infarcts (with the highest
mortality risk and greatest treatment benefit)48 report
early, whereas elderly patients tend to wait longer.49,50
Therefore, the randomised comparisons of earlier versus
later therapy may provide better estimates of the
delay/effect relation than comparison of different cohorts
from the large randomised trials. Furthermore, the formal
statistical approach has a major influence on the results of
the FTT analysis. Results from previous investigations
indicating a non-linear delay/benefit relation (eg, the
GISSI-1 clinical trial12) were considered hypothesis-
generating, whereas the outcomes of experimental and
prehospital trials were dismissed.4 In the combined trial
data (summarised by five datapoints) no significant
deviation of linearity was observed and thus the hypothesis
of a linear delay/benefit relation was not rejected in the
FTT analysis. By contrast, our alternative analysis
supports a non-linear relation which is in agreement with
the experimental and prehospital data (figure 4). A large
reduction in mortality was detected in patients treated
within 1 h of symptom onset (65 [14] per 1000 treated).
The decrease in benefit in the 0·75–1·6 h interval (51 min)
was roughly 33 lives per 1000 treated per hour (from 65
[14] to 37 [9]), and declined rapidly to about 3·3 lives per
h in the 1·6–4·0 h interval (from 37 [9] to 29 [5]), and
only 1·4 lives per h after this period (from 29 [5] at 4·0 h
to 9 [7] at 18·0 h). The delay/benefit relation could be
significantly better described by a non-linear (+x+x1)
rather than a linear (+x) function. Although the
goodness of fit within the tabulated data of the separate
trials remains limited (R2=0·32), the non-linear function
does fit very well with the benefit estimations in the six
time-to-treatment groups (figure 4).
The concept of a first golden hour in myocardial
infarction is supported by our analysis, although our
estimations may be biased by differences in baseline
characteristics between time-to-treatment groups, the
unknown delay between randomisation and actual
initiation of therapy and coronary reperfusion, and the
unknown individual delays within the reported studies.
The benefit of thrombolytic therapy initiated within
30–60 min after onset of symptoms can be estimated at
60–80 additional patients alive at 1 month per 1000
treated compared with conventional therapy. The benefit
of therapy within 1–3 h is in the range 30–50 per 1000
treated.
From a clinical standpoint, the challenge is to initiate
fibrinolytic treatment within the first 2 to 3 h after
symptom onset. A first important step will be to increase
public awareness of the need to reduce delay in seeking
medical help for cardiac symptoms. Second, as an aid to
rapid diagnosis when there is chest pain suggestive of
infarction, the general practitioner or ambulance team
should obtain—preferably on-site—a computer-
interpreted standard 12-lead ECG.51 With certainty of
diagnosis, thrombolytic therapy may be started quickly,
before hospital admission. Patients in whom myocardial
infarction cannot be confirmed on site, and those
presenting directly to the emergency department, may still
benefit from emergency room initiation of thrombolytic
infusion. Avoidance of unnecessary treatment delay
should be given top priority so as to improve the survival
prospects of patients with suspected evolving myocardial
infarction.52
References
1 Vermeer F, Simoons ML, Bär FW, et al. Which patients benefit most
from early thrombolytic therapy with intracoronary streptokinase.
Circulation 1986; 74: 1379–89.
2 Weaver WD. Time to thrombolytic treatment: factors affecting delay
and their influence on outcome. J Am Coll Cardiol 1995; 25: 3S–9S.
3 Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront
phenomenon of ischemic cell death: 1 myocardial infarct size versus
duration of coronary occlusion in dogs. Circulation 1977; 56: 786–94.
4 Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and major
morbidity results from all randomised trials of more than 1000
patients. Lancet 1994; 343: 311–22.
5 Flameng W, Lesaffre E, Vanhaecke J. Determinants of infarct size in
non-human primates. Bas Res Cardiol 1990; 85: 392–403.
6 Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute
myocardial infarction: effect of timing and modulating factors in
experimental models. Am J Cardiol 1993; 72: 13G–21G.
7 Dorado DG, Théroux P, Elizaga J, et al. Myocardial infarction in the
pig heart model: infarct size and duration of coronary occlusion.
Cardiovasc Res 1987; 21: 537–44.
8 Schaper W, Binz K, Sass S, Winkler B. Influence of collateral blood
flow and of variations in MVO2 on tissue-ATP content in ischemic and
infarcted myocardium. J Mol Cell Cardiol 1987; 19: 19–37.
9 Hermens WT, Willems GM, Nijssen KM, Simoons ML. Effect of
thrombolytic treatment delay on myocardial infarction size. Lancet
1992; 340: 1297.
10 McNeill AJ, Flannery DJ, Wilson CM, et al. Thrombolytic therapy
within one hour of the onset of acute myocardial infarction. Q J Med
1991; 79: 487–94.
11 Davies GJ, Chierchia S, Maseri A. Prevention of myocardial infarction
by very early treatment with intracoronary streptokinase. N Engl J Med
1984; 311: 1488–92.
12 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto
miocardico (GISSI). Effectiveness of intravenous thrombolytic
treatment in acute myocardial infarction. Lancet 1986; i: 397–401.
13 Van de Werf F, Arnold AER, for the European Cooperative Study
Group for recombinant tissue type plasminogen activator: intravenous
tissue plasminogen activator and size of infarct, left ventricular
function, and survival in acute myocardial infarction. BMJ 1988; 297:
1374–79.
14 McNeill AJ, Cunningham SR, Flannery DJ, et al. A double-blind
placebo-controlled study of early and late adminstration of
recombinant tissue plasminogen activator in acute myocardial
infarction. Br Heart J 1989; 61: 316–21.
15 Schofer J, Büttner J, Geng G, et al. Prehospital thrombolysis in acute
myocardial infarction. Am J Cardiol 1990; 66: 1429–33.
16 Barbash GI, Roth A, Hod H, et al. Improved survival but not left
ventricular function with early and prehospital treatment with tissue
plasminogen activator in acute myocardial infarction. Am J Cardiol
1990; 66: 261–66.
17 Castaigne AD, Hervé C, Duval-Moulin AM, et al. Pre-hospital use of
APSAC: results of a placebo-controlled study. Am J Cardiol 1989; 64:
30A–33A.
18 McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in a
774 Vol 348 • September 21, 1996
THE LANCET
Vol 348 • September 21, 1996 775
rural community: short and long-term survival. Cardiovasc Drugs Ther
1992; 6: 369–72.
19 Great Group. Feasibility, safety, and efficacy of domiciliary
thrombolysis by general practitioners: Grampian region early
anistreplase trial. BMJ 1992; 305: 548–53.
20 Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated
vs hospital-initiated thrombolytic therapy: the Myocardial Infarction
Triage and Intervention Trial. JAMA 1993; 270: 1211–16.
21 The European Myocardial Infarction Project Group. Prehospital
thrombolytic therapy in patients with suspected acute myocardial
infarction. N Engl J Med 1993; 329: 383–89.
22 Fath-Ordoubadi F, Al-Mohammad A, Huehns TY, Beat KJ. Meta-
analysis of randomised trials of prehospital versus hospital
thrombolysis. Circulation 1994; 90: I–325 (abstr).
23 Fath-Ordoubadi F, Beatt KJ. Fibrinolytic therapy in suspected acute
myocardial infarction. Lancet 1994; 343: 912.
24 Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality
and the timing of thrombolytic therapy: a meta-analysis. J Am Coll
Cardiol 1990; 16: 359–67.
25 Kennedy JW, Ritchie JL, Davies KB, Fritz JK. Western Washington
randomized trial of intracoronary streptokinase in acute myocardial
infarction. N Engl J Med 1983; 309: 1477–82.
26 Verstraete M, Bleifeld W, Brower RW, et al. Double-blind randomised
trial of intravenous tissue-type plasminogen activator versus placebo in
acute myocardial infarction. Lancet 1985; ii: 965–99.
27 Simoons ML, Serruys PW, Van den Brand M, et al. Improved survival
after early thrombolysis in acute myocardial infarction: a randomised
trial by the Interuniversity Cardiology Institute in The Netherlands.
Lancet 1985; ii: 578–82.
28 Ikram S, Lewis S, Bucknall C, et al. Treatment of acute myocardial
infarction with anisoylated plasminogen streptokinase activator
complex. BMJ 1986; 293: 786–89.
29 The I.S.A.M. Study Group. A prospective trial of intravenous
streptokinase in acute myocardial infarction (I.S.A.M.): mortality,
morbidity, and infarct size at 21 days. N Engl J Med 1986; 314:
1465–71.
30 White HD, Norris RM, Brown MA, et al. Effect of intravenous
streptokinase on left ventricular function and early survival after acute
myocardial infarction. N Engl J Med 1987; 317: 850–55.
31 ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomised trial of intravenous streptokinase, oral aspirin,
both, or neither among 17 187 cases of suspected acute myocardial
infarction: ISIS-2. Lancet 1988; ii: 349–60.
32 AIMS (APSAC Intervention Mortality Study) Trial Study Group.
Effects of intravenous APSAC on mortality after acute myocardial
infarction: preliminary report of a placebo-controlled clinical trial.
Lancet 1988; i: 545–49.
33 Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM,
Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen
activator for mortality reduction in acute myocardial infarction. Lancet
1988; ii: 525–30.
34 Brunelli C, Spallarossa P, Ghigliotti G, et al. Peaking time of creatine-
kinase MB in patients treated with urokinase or conventionally during
acute myocardial infarction: is it really a clue to reperfusion?
Cardiologia 1988; 33: 669–74.
35 National Heart Foundation of Australia coronary thrombolysis group.
Coronary thrombolysis and myocardial salvage by tissue plasminogen
activator given up to 4 h after onset of myocardial infarction. Lancet
1988; i: 203–07.
36 O’Rourke M, Baron D, Keogh A, et al. Limitation of myocardial
infarction by early infusion of recombinant tissue-type plasminogen
activator. Circulation 1988; 77: 1311–15.
37 Kennedy JW, Martin GV, David KB, et al. The Western Washington
intravenous streptokinase in acute myocardial infarction randomized
trial. Circulation 1988; 77: 345–52.
38 Rentrop KP, Feit F, Sherman W, Thornton JC. Serial angiographic
assessment of coronary artery obstruction and collateral flow in acute
myocardial infarction: report from the second Mount Sinai-New York
University reperfusion trial. Circulation 1989; 90: 1166–75.
39 Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen
activator: Toronto (TPAT) placebo-controlled randomized trial in
acute myocardial infarction. J Am Coll Cardiol 1989; 13: 1469–76.
40 The Thrombolysis Early in Acute Heart Attack Trial study group.
Very early thrombolytic therapy in suspected acute myocardial
infarction. Am J Cardiol 1990; 65: 401–07.
41 LATE Study Group. Late Assessment of Thrombolytic Efficacy
(LATE) study with alteplase 6–24 h after onset of acute myocardial
infarction. Lancet 1993; 342: 759–66.
42 EMERAS (Estudio Multicentrico Esteptoquinasa Republicas de
America del Sur) Collaborative Group. Randomised trial of late
thrombolysis in patients with suspected acute myocardial infarction.
Lancet 1993; 342: 767–72.
43 Rossi P, Bolognese L, on behalf of Urochinasi per la Sistemica
nell’Infarto Myocardico (USIM) Collaborative Group. Comparison of
intravenous urokinase plus heparin versus heparin alone in acute
myocardial infarction. Am J Cardiol 1991; 68: 585–92.
44 ISIS-3 (Third International Study of Infarct Survival) Collaborative
Group. ISIS-3: a randomised comparison of streptokinase vs tissue
plasminogen activator vs anistreplase and of aspirin plus heparin vs
aspirin alone among 41,299 cases of suspected acute myocardial
infarction. Lancet 1992; 339: 753–70.
45 Brunelli C, Spallarossa P, Ghigliotta G, Ianetti M, Caponnetto S.
Thrombolysis in refractory unstable angina. Am J Cardiol 1991; 68:
110B–18B.
46 Bär FW, Verheugt FW, Col J, et al. Thrombolysis in patients with
unstable angina improves the angiographic but not the clinical
outcome: results of UNASEM, a multicenter, randomised, placebo-
controlled, clincial trial with anistreplase. Circulation 1992; 86: 131–37.
47 The TIMI IIIB investigators. Effects of tissue plasminogen activator
and a comparison of early invasive and conservative strategies in
unstable angina and non-q-wave myocardial infarction: results of the
TIMI IIIB trial. Circulation 1994; 89: 1545–56.
48 Simoons ML, Arnold AER. Tailored thrombolytic therapy. A
perspective. Circulation 1993; 88: 2556–64.
49 Turi ZG, Stone PH, Muller JE. Implications for acute intervention
related to time of hospital arrival in acute myocardial infarction. Am J
Cardiol 1986; 58: 203–09.
50 Yarzebski J, Goldberg RJ, Gore JM, Alpert JS. Temporal trends and
factors associated with extent of delay to hospital arrival in patients
with acute myocardial infarction: the Worcester heart attack study. Am
Heart J 1994; 128: 255–63.
51 Bouten MJM, Simoons ML, Hartman JAM, Van Miltenburg AJM,
Van der Does E, Pool J. Prehospital thrombolysis with alteplase (rt-
PA) in acute myocardial infarction. Eur J Heart 1992; 13: 925–31.
52 Guidelines. Acute myocardial infarction: pre-hospital and in-hospital
management. The task force on the management of acute myocardial
infarction of the European society of cardiology. Eur Heart J 1996; 17:
43–63.
